Vyome Holdings Inc 2025年季度报告

QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 ☒ For the quarterly period endedJune 30, 2025OR TRANSITION REPORT PURSUANT TO SECTION 13OR15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission file number:1-37897 RESHAPE LIFESCIENCES INC. 26-1828101(IRS EmployerIdentification No.) Delaware(State or other jurisdictionof incorporation or organization) 18 Technology Dr, Suite 110,Irvine,California92618(Address of principal executive offices) (zip code)(949)429-6680(Registrant’s telephone number, including area code) Name of Each Exchange on whichRegisteredTheNasdaqCapital Market RSLS Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that theregistrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File requiredto be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months(or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the ExchangeAct. AcceleratedFiler☐SmallerReportingCompany☒Emerging GrowthCompany☐ LargeAcceleratedFiler☐ Non-accelerated Filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ExchangeAct).Yes☐No☒ As of August 8, 2025,2,693,338shares of the registrant’s Common Stock were outstanding. INDEX PART I – FINANCIAL INFORMATION Item1.Condensed Consolidated Financial Statements (unaudited)3Condensed Consolidated Balance Sheets as of June 30, 2025 and December31, 20243Condensed Consolidated Statements of Operations for the three and six months ended June 30,2025 and 20244Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June30, 2025 and 20245Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June30, 2025 and 20246Condensed Consolidated Statements of Cash Flows for the three and six months ended June 30, 2025and 20248Notes to Condensed Consolidated Financial Statements9Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item4.Controls and Procedures29 PART II – OTHER INFORMATION Item1.Legal Proceedings30Item1A.Risk Factors31Item2.Unregistered Sales of Equity Securities and Use of Proceeds31Item3.Defaults Upon Senior Securities31Item4.Mine Safety Disclosures31Item5.Other Information31Item6.Exhibits32SIGNATURES33 PARTI – FINANCIAL INFORMATION ITEM1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS RESHAPE LIFESCIENCES INC.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited) RESHAPE LIFESCIENCES INC.Condensed Consolidated Statements of Operations(in thousands, except share and per share data)(unaudited) RESHAPE LIFESCIENCES INC.Condensed Consolidated Statements of Comprehensive Loss(in thousands)(unaudited) RESHAPE LIFESCIENCES INC.Condensed Consolidated Statements of Stockholders’ Equity(in thousands, except share data)(unaudited) RESHAPE LIFESCIENCES INC.Condensed Consolidated Statements of Stockholders’ Equity (Continued)(in thousands, except share data)(unaudited) See accompanying notes to Condensed Consolidated Financial Statements. RESHAPE LIFESCIENCES INC.Condensed Consolidated Statements of Cash Flows(in thousands)(unaudited) See accompanying notes to Condensed Consolidated Financial Statements. ReShape Lifesciences Inc.Notes to Condensed Consolidated Financial Statements (1)Basis of Presentation The accompanying interim condensed consolidated financial statements and related disclosures of ReshapeLifesciences Inc. (the “Company” or “ReShape”) have been prepared pursuant to the rules and regulations of theSecurities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financialstatements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31,2024, filed on April 4, 2025. Certain information and footnote disclosures normally included in financialstatements prepared in accordance with ge